Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21664661 | 0.85 | HRH3 (0.37) | TSHRSMN1; SMN2MAPTHSD17B10MEN1 | |
| SCHEMBL16134044 | 0.84 | TSHR (0.49) | TSHRSMN1; SMN2MAPTHSD17B10MEN1 | |
| SCHEMBL25791934 | 0.84 | MEN1 (0.38) | TSHRSMN1; SMN2MEN1KMT2AFAAH | |
| SCHEMBL17524776 | 0.84 | TSHR (0.51) | TSHRSMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL23320108 | 0.83 | TSHR (0.47) | TSHRSMN1; SMN2HPGD | |
| SCHEMBL24486573 | 0.82 | TSHR (0.46) | TSHRSMN1; SMN2MAPTHSD17B10MEN1 | |
| SCHEMBL25835006 | 0.81 | TSHR (0.47) | TSHRSMN1; SMN2MAPTHSD17B10MEN1 | |
| SCHEMBL21965675 | 0.81 | MEN1 (0.44) | TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL20325690 | 0.79 | HRH3 (0.37) | TSHRSMN1; SMN2MAPTHSD17B10MEN1 | |
| SCHEMBL25851515 | 0.79 | MEN1 (0.47) | TSHRMAPTHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | TSHR 4378/4885SMN1; SMN2 4743/4885MAPT 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.